Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec and Gemzar in refractory malignant mesothelioma
NCT00551252Phase 2Unknown
- Sponsor
- Gruppo Italiano Mesotelioma
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in malignant mesothelioma, sponsored by Gruppo Italiano Mesotelioma. Status: unknown.
02
Drugs
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00551252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551252.